A simple, reliable method for high-throughput screening for diabetes drugs using 3D β-cell spheroids

Area of Science:

• Endocrinology
• Pharmacology
• Cell Biology

Background:

• Traditional 2D β-cell cultures lack predictive power for in vivo drug responses.
• Human islet spheroids reduce variability but are costly and difficult to obtain.
• Developing robust and scalable models for diabetes drug discovery is crucial.

Purpose of the Study:

• To evaluate 3D β-cell spheroids from a cultured cell line (INS-1832/13) as a high-throughput screening (HTS) assay.
• To compare the performance of 2D cultures, 3D spheroids, and human islet spheroids in response to various stimuli.
• To assess the suitability of these models for predicting in vivo drug responses.

Main Methods:

• Cultured INS-1832/13 β-cells were used in 2D and 3D spheroid formats.
• Human donor islets were formed into spheroids for comparison.
• All models were tested using glucose, glybenclamide, caffeine, nifedipine, and diazoxide.
• Assay quality was assessed using Z' factor calculations.

Main Results:

• 3D β-cell spheroids and 2D cultures showed higher glucose sensitivity than human islet spheroids.
• Responses to glybenclamide and caffeine varied, with cultured cells often showing greater sensitivity.
• 3D β-cell spheroids consistently met criteria for excellent drug screening assays.
• Responses to insulin secretion inhibitors (nifedipine, diazoxide) were similar across models.

Conclusions:

• 3D β-cell spheroids derived from cultured cell lines provide a sensitive and predictive HTS assay for diabetes drug discovery.
• This model overcomes limitations associated with 2D cultures and scarce human islets.
• 3D spheroids offer a consistent and scalable alternative for evaluating drug efficacy and predicting in vivo outcomes.